Aquestive ($AQST): Anaphylm PDUFA Set for March 16, 2027 — How Is the Company Preparing for Launch?

01 Bull / Base / Bear Framework

September 29, 2026 update. October 14 is the effective date of a governance appointment. On October 15 the FDA set a March 16, 2027 PDUFA goal date for the September resubmission. The constructive scenario requires a favorable regulatory outcome followed by launch execution; the adverse scenario still includes additional-information requests, delay, non-approval and spending before material product revenue. Company source

October 5 update: Anaphylm was resubmitted on September 16, 2026 (announced September 17). The earlier Q3 filing target was met by the September 16 submission. On October 15 the FDA classified the resubmission as Class 2 and set a PDUFA goal date of March 16, 2027; the open question is whether the response satisfies a letter that also raised film tolerability and misuse pharmacokinetics.

Constructive. Improved usability, supportive preliminary PK and a revenue-generating manufacturing base support further execution.

Cautious. FDA acceptance, review timing and approval remain unconfirmed. Launch costs and conditional funding limit flexibility.

02 Bull Case

The strongest constructive point is that the January CRL appears to have been narrow enough to repair without rebuilding the clinical or CMC package. The required human-factors and PK studies are complete, usability improved substantially, preliminary PK endpoints were met and no administration errors were observed in the self-administration arm.

The Q2 print adds operational support. Revenue rose 38%, manufacturing volume increased about 30%, gross margin expanded and adjusted EBITDA loss narrowed. A stable partnered business cannot guarantee Anaphylm success, but it reduces the resemblance to a single-asset pre-revenue shell.

Anaphylm remains differentiated. A portable, device-free oral epinephrine option could address needle aversion and carry behavior. If FDA accepts the package and payers support access, an allergist-first strategy may provide a focused route into the market rather than requiring immediate broad primary-care scale.

Libervant creates a second 2027 path through the Eton license: the ages 6–11 filing, tentative approvals and the January 2027 exclusivity reference point now drive milestone and royalty income rather than an Aquestive launch. AQST-108 adds a longer-duration platform asset, and atopic dermatitis offers a large potential market if clinical efficacy is eventually demonstrated.

Finally, the company has a defined approval-contingent financing framework. A potential $95 million from RTW and Oaktree after approval could help fund launch without relying entirely on an immediate equity raise. The constructive case still depends on meeting the conditions and controlling spending before those funds become available.

03 Bear Case and Red Flags

The required studies are complete, but the FDA has not yet decided on them in the resubmitted NDA. Topline analyses may change with final review, the agency can request additional information or work, and expedited review is not guaranteed. Human factors remain a core safety issue for a rescue product rather than a cosmetic packaging detail.

The FDA’s own account of the January letter is wider than the company’s. The agency published the complete response letter, and besides pouch opening and film placement it states that “tolerability of dibutepinephrine sublingual film is a concern”, citing pediatric participants who reported tingling, burning or taste that would lead them to remove the film and “the high rate of local adverse events reported in the pivotal PK trials”. It asked for pharmacokinetics under three conditions: film chewed with and without swallowing, film placed at alternative sites such as the top of the tongue or the roof of the mouth, and self-administration with the final instructions, each against trained-staff dosing and an injected epinephrine product. The August materials report the self-administration arm and, for the alternative-site condition, a top-of-tongue arm; they do not report a chewed-film arm, a point Aquestive said in March it and the FDA had “aligned on the concept” of handling through labeling. On tolerability, the company reported on August 10 that no participant in the new human factors study and no subject in the PK study removed the film prematurely, with no serious adverse events and no adverse events leading to study drug discontinuation in the PK study; these are topline company data whose sufficiency the FDA will judge. The letter also notes a citizen petition filed on October 1, 2025 by ARS Pharmaceuticals, maker of the nasal spray neffy, about Anaphylm. FDA complete response letter →

The unchanged guidance contains a financial warning. First-half adjusted EBITDA loss was only $7.0 million, while the full-year guide remains $30 million to $35 million. The implied $23 million to $28 million second-half loss could consume liquidity quickly if regulatory timing slips.

Gross cash overstates flexibility. The company also carries debt, royalty obligations and a large future-revenue liability. The additional $95 million described in the supplemental materials is approval-contingent. Historical share dilution is material, with Q2 weighted-average shares about 26% above the prior-year quarter.

Competition is real. Autoinjectors remain standard, nasal epinephrine has already created a needle-free alternative, and Anaphylm must earn physician confidence, payer coverage and patient adoption. A differentiated dosage form is not automatically a differentiated commercial outcome.

Libervant is not current U.S. revenue. Tentative approval, exclusivity, litigation history and FDA procedure can still delay access. The ages 6–11 filing adds opportunity but also another regulatory process. AQST-108 remains too early to support the valuation if the two nearer proprietary programs disappoint.

Management credibility is therefore a red flag to monitor, not a conclusion to assume. The third-quarter filing promise was kept with the September 16 submission, announced on September 17; the remaining tests are transparent review expectations, staged commercial spending, disciplined financing and precise disclosure of what FDA—not management—has actually confirmed.

What Would Falsify This Reading

Aquestive is now a company whose whole value sits with an FDA reviewer: an application resubmitted, a usability problem addressed, and a launch that cannot be planned until the agency answers. Five things would show that reading to be wrong, and each is checkable against a company release or a regulator record.

• The review clock slips. On October 15, 2026 the FDA accepted the resubmission as a Class 2 response and set a PDUFA goal date of March 16, 2027. A major amendment, a request for more information or a second complete response letter would move or end that timetable.
• The answer to the January complete response letter is judged insufficient. The letter of January 30, 2026 asked for a new human factors study on a redesigned pouch and instructions, pharmacokinetics under misuse conditions such as a chewed or misplaced film, and an answer on film tolerability. The company reports that median pouch-opening time fell from 17 seconds to 3 and that no protocol-defined use errors were observed in the self-administration arm. Whether that answers the question is the agency’s judgement, not the company’s.
• The international filings land, or do not. The company targets Canada before the end of 2026 and the European Union in the first quarter of 2027. Those are guidance, not submissions. A filing in either would show the dossier travelling; silence past the windows would suggest it is not ready to.
• The cash reaches the launch. $98.5 million at June 30, 2026 against a quarterly net loss of $22.9 million, revenue of $13.8 million and full-year guidance of $46 to $50 million, with the Oaktree facility in the capital structure. A commercial build for a first branded launch, on an uncertain approval date, is the phase where that balance is tested.
• Libervant or the AdrenaVerse programmes become a second business. Libervant, licensed to Eton, has a tentative approval and AQST-108 sits behind it. Each is currently an option rather than a revenue line. A full approval or a dated readout would give this company something that does not depend on the Anaphylm review.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

04 Q2 2026 Earnings: Better Operations, a Distorted GAAP Loss and an Unchanged Spending Plan

Aquestive released second-quarter results on August 11, 2026. The operating print was stronger than the headline net loss suggests. Revenue increased 38% to $13.819 million, adjusted EBITDA loss narrowed to $5.192 million from $9.344 million, and GAAP gross margin expanded to 71% from 54%. The reported $22.864 million net loss was dominated by an $11.683 million one-time loss on extinguishment of the old 13.5% notes during the Oaktree refinancing.

EPS quality: the -$0.18 headline overstates recurring operating deterioration

The quarter requires an EPS-quality bridge. The company repaid the old 13.5% notes when the Oaktree facility closed and recorded an $11.683 million loss equal to the difference between the notes’ carrying value and payoff amount. Without that one-time item, the company says net loss would have been $11.2 million. Operating loss and adjusted EBITDA both improved year over year, so the correct conclusion is not that the underlying business suddenly deteriorated by the full GAAP-loss increase.

That does not make the quarter profitable. SG&A rose to $14.1 million and adjusted EBITDA remained negative. Interest expense, royalty obligations and the future-revenue liability also remain part of the economics. At June 30 the balance sheet carried $50.654 million of long-term debt net, $27.886 million of royalty obligations ($27.835 million non-current) and a $62.168 million liability related to the sale of future revenue ($61.168 million non-current).

Manufacturing was the clean operating positive

Aquestive manufactured approximately 48 million doses in Q2 2026, up from approximately 37 million a year earlier, an increase of about 30%. The company continues to manufacture Suboxone for Indivior and supplies products tied to Sympazan, Ondif and Emylif collaborations. Management described manufacturing as steady and said its largely U.S.-based manufacturing and intellectual-property footprint remains largely unaffected by implemented and proposed tariffs in the near term.

Guidance was not raised, and the implied second-half loss matters

Full-year 2026 guidance remains $46 million to $50 million of revenue and a non-GAAP adjusted EBITDA loss of $30 million to $35 million. First-half revenue was already $28.265 million, up 51% year over year, leaving an implied $17.735 million to $21.735 million for the second half. First-half adjusted EBITDA loss was $6.965 million, so the unchanged annual range mathematically implies a much larger second-half loss of roughly $23 million to $28 million.

That implied acceleration is an inference from company guidance, not a new line-item forecast issued by management. It is nevertheless important: future management updates should explain how much of the planned second-half spending relates to the Anaphylm resubmission, medical affairs, payer work, allergist-first launch preparation, AQST-108 studies and other corporate costs.

Cash is real; the additional $95 million is approval-contingent

The company ended June with $98.5 million of cash. Its Q2 supplemental materials also point to $75 million potentially available under the RTW funding agreement and $20 million of additional Oaktree debt upon Anaphylm approval. Those two sources could strengthen launch funding if the approval conditions are met, but they are not part of the June cash balance and are not unconditional liquidity. On October 14, 2026 Aquestive announced an exclusive U.S. license of Libervant to Eton Pharmaceuticals; ex-U.S. out-licensing for Anaphylm remains under evaluation.

05 Next Catalyst

The Anaphylm NDA was resubmitted on September 16, 2026 (announced September 17), which closes the Q3 2026 target the company had set for itself. On October 15, 2026 Aquestive said the FDA acknowledged the resubmission as complete, classified it as a Class 2 response and assigned a PDUFA goal date of March 16, 2027. Source

Review clock: the PDUFA goals give two months for a Class 1 resubmission and six months for a Class 2, counted from receipt. The FDA classified the resubmission as Class 2 and set the goal date at March 16, 2027. FDA →

Financing deadlines: the RTW purchase price of $75 million is payable only if Anaphylm is approved by June 30, 2027, after Amendment No. 1 of March 3, 2026 moved the deadline, and the $20 million Oaktree Tranche B can be drawn only after an approval received before the same date. Form 10-Q →

Third-quarter results: no date announced as of October 5; the third-quarter 2025 report came on November 5, 2025. It will be the first report to show cash after the resubmission costs.

The September calendar has been worked through: investor meetings on September 8 and 10, Cantor on September 9 and H.C. Wainwright on September 14, the last of which was filed as an exhibit to the September 17 Form 8-K. These were information events, not FDA decisions.

International sequence: Health Canada filing remains targeted by the end of 2026, the European Union filing in Q1 2027, and additional markets including the United Kingdom during 2027.

Libervant sequence: FDA action on the Q2 2026 filing for patients aged 6–11 (goal date March 29, 2027, as cited in the October 14 Eton license announcement), any appellate or regulatory change affecting younger-patient access, and the January 10, 2027 expiration of the Valtoco orphan exclusivity blocking access for patients aged 12 and older, and a D.C. Circuit decision on the age 2–5 appeal that the company expects later this year.

AQST-108 sequence: additional preclinical work in the second half of 2026 and a planned single-ascending-dose/multiple-ascending-dose study in the first half of 2027, with atopic dermatitis now highlighted alongside other dermatology opportunities.

September conference schedule

06 Fast Facts

Q2 release — August 11, 2026

The snapshot shows why AQST is not only a binary FDA ticker. Anaphylm dominates near-term valuation, but the company has a manufacturing and royalty base, Libervant could become a second proprietary commercial asset, and AQST-108 provides earlier-stage platform optionality. The trade-off is that approval and launch preparation require more spending before proprietary-product revenue becomes durable.

07 Executive Summary

September 29, 2026 update. The governance addition supports commercial oversight, while the investment case still turns on FDA assessment of the resubmitted Anaphylm application and, if approved, execution of an actual launch. The board release contains no new human-factors, pharmacokinetic or efficacy result. Company source

Aquestive Therapeutics sits between a pre-revenue biotech and a mature specialty-pharma company. It has real manufacturing and royalty revenue, but the equity remains dominated by the regulatory and commercial value of Anaphylm, its investigational dibutepinephrine sublingual film for severe allergic reactions including anaphylaxis.

The August 10 human-factors and PK results materially advanced the CRL-repair story. The required studies were completed, usability measures improved sharply and the PK study met its preliminary primary endpoints. On August 11 management again said the Q3 2026 NDA resubmission remains on track and described the filing as coming in the next several weeks. The resubmission followed on September 16, 2026 (announced September 17), inside the promised window. On October 15 the FDA accepted it as a Class 2 resubmission and set a PDUFA goal date of March 16, 2027.

Q2 added a better operating base than the GAAP net-loss headline implies. Revenue rose 38% to $13.8 million, GAAP gross margin expanded to 71%, operating loss narrowed to $8.2 million and adjusted EBITDA loss narrowed to $5.2 million. The $22.9 million GAAP net loss included an $11.7 million one-time debt-extinguishment loss tied to replacing the old 13.5% notes with Oaktree financing.

Cash declined to $98.5 million from $110.7 million at March 31. The approval-contingent launch-funding framework includes a potential $75 million under the RTW agreement and $20 million of additional Oaktree debt, but those amounts are not current cash. The balance sheet also includes debt, royalty obligations and a future-revenue liability, so gross cash alone does not describe the full capital structure.

The unchanged 2026 guidance creates the most important financial question for the conference call. With first-half revenue of $28.3 million and adjusted EBITDA loss of $7.0 million, the annual ranges mathematically imply $17.7 million to $21.7 million of second-half revenue and a much larger $23 million to $28 million second-half adjusted EBITDA loss. That may reflect launch and development investment, but management needs to explain the cadence.

Anaphylm is no longer the only proprietary value layer. Libervant remains tentatively approved for patients aged 12 and older, full access for that group is expected to become possible after competing orphan exclusivity expires in January 2027, and Aquestive disclosed that it filed for ages 6–11 in Q2 2026. Market access, legal procedure, payer coverage and launch execution still prevent investors from treating the company’s >$100 million opportunity estimate as current revenue.

AQST-108 adds earlier-stage optionality. The company completed Phase 1 work without identified safety concerns, is expanding the program toward inflammatory dermatology indications including atopic dermatitis, and plans additional preclinical work in the second half of 2026 and SAD/MAD clinical work in the first half of 2027.

The disciplined thesis is therefore a three-layer story. Anaphylm is the near-term binary and the largest value driver. Libervant, licensed to Eton in October 2026, is a potential 2027 source of milestones and royalties with lower classic development risk but unresolved access risk. AQST-108 is platform optionality rather than the main trade. The financial statements show enough liquidity to reach the resubmission, but the unchanged guidance warns that the expensive part of launch preparation may still be ahead.

08 Why AQST Matters Now

AQST matters now because three clocks are running at once. The first is the Anaphylm regulatory clock: the studies required by the CRL are complete and the resubmission went in on September 16, 2026 (announced September 17), the FDA has classified it as Class 2 with a March 16, 2027 goal date, and the agency’s judgement on the package still lies ahead. The second is the spending clock: unchanged full-year guidance implies a much larger adjusted EBITDA loss in the second half. The third is the 2027 commercial clock, when an Anaphylm launch would require resources; Libervant’s launch is now Eton’s responsibility.

The product concept remains easy to understand. Anaphylm aims to remove both the needle and the device from emergency epinephrine treatment. A postage-stamp-sized film could be easier to carry and less intimidating than an autoinjector. But an emergency product must also open quickly, be placed correctly and deliver a reliable exposure profile under stress. That is why the human-factors repair matters as much as the formulation.

The August 10 data reduced one layer of risk by showing major improvement in pouch opening and administration and supportive preliminary PK. They did not remove the FDA layer. The agency has not yet ruled on the package now inside the resubmitted NDA, and expedited review is only a company request until FDA says otherwise.

The Q2 print strengthens the non-binary side of the story. Manufacturing volume reached approximately 48 million doses and gross margin expanded, providing evidence that the partnered business can contribute while proprietary assets advance. Yet the company is still loss-making, carries complex funding obligations and is preparing for a much more expensive commercial phase.

09 Company Overview: Manufacturing Base, Proprietary Films and an Epinephrine Platform

Aquestive develops and manufactures oral, buccal, sublingual and topical products around its film and prodrug capabilities. The legacy operating base is not theoretical: in Q2 2026 the company manufactured approximately 48 million doses and generated $11.9 million of manufacture and supply revenue.

Commercial collaborations include Suboxone sublingual film for Indivior, Sympazan oral film now linked to Cosette, Ondif oral film for Hypera in Brazil and Emylif oral film for Zambon in Europe. Royalty-based products, including Sympazan, also contributed to Q2 revenue. Management says the largely U.S.-based manufacturing and intellectual-property footprint remains largely unaffected by implemented and proposed tariffs in the near term.

The proprietary portfolio has three different maturity levels. Anaphylm is the dominant near-term catalyst and remains in FDA repair-and-resubmission mode. Libervant has crossed much of the quality, safety and efficacy review burden but remains constrained by orphan exclusivity, litigation history and the mechanics of final approval and market access. AQST-108 and the broader AdrenaVerse platform are earlier-stage programs aimed at controlling epinephrine absorption and conversion for other indications.

This structure creates diversification but also competition for capital. Manufacturing and royalties can help fund operations, Libervant now contributes through the Eton license (milestones, royalties and supply), and AQST-108 can extend the platform. None of those layers removes the near-term dependence of the equity on FDA’s handling of the Anaphylm resubmission.

10 Anaphylm: Product Logic and Regulatory Sensitivity

Anaphylm is being developed for the treatment of Type I allergic reactions, including anaphylaxis, in patients who require emergency epinephrine. The medical logic behind epinephrine rescue is well understood: anaphylaxis can progress rapidly, and epinephrine is the central rescue therapy used to stabilize airway, blood pressure and systemic response.

The commercial problem is not only whether epinephrine works. It is whether patients carry the product, recognize the emergency, overcome hesitation and administer it correctly and quickly. That is where Anaphylm’s promise comes from. A small film could be more portable than a device, easier to keep in a wallet or phone case, and less intimidating than a needle-based auto-injector. For patients who dislike needles, hesitate to inject themselves, or fail to carry bulky devices, a film could theoretically improve real-world readiness.

But that same logic explains the FDA’s sensitivity. Emergency products face a brutal usability standard. A product used in panic, by a child, caregiver, school nurse, emergency medical technician or passerby, cannot rely on perfect training. Packaging must open quickly. Instructions must be clear. The dose form must be handled correctly. The film must be placed correctly. Changes to pouch opening, labeling or administration instructions can affect how the product is used and, potentially, how drug exposure compares with prior studies.

In this setting, human factors are not cosmetic. They are core product risk. A cool formulation is not enough if FDA is not convinced users can access and administer it correctly during emergencies.

11 Anaphylm Regulatory Timeline

12 The January 2026 CRL: Bad News, But Not the Worst Kind of Bad News

The January 2026 CRL is the central event in the current AQST story. January 31, 2026 is now history. What matters is how the CRL reshaped the probability, timing, cost and competitive positioning of Anaphylm.

According to Aquestive, the CRL deficiencies were related to packaging and administration. The company said FDA requested changes tied to how the product is opened and used, a new human-factors validation study, and a supportive PK study after human-factors issues are addressed. Reuters reported that the FDA’s concerns involved packaging and use issues observed in a study where some users struggled to open the pouch or place the film correctly, which could create safety risk in an emergency setting.

The positive interpretation is that this looks fixable. The CRL, as described by the company, does not appear to be a rejection of epinephrine exposure, the entire clinical package, or manufacturing readiness. Aquestive has repeatedly stated that the CRL did not identify CMC deficiencies and did not question clinical comparability to auto-injectors.

What the FDA’s published letter adds

The FDA now publishes complete response letters, and the Anaphylm letter of January 30, 2026 (NDA 219870) is in its public database. It confirms that the deficiencies sit under human factors, clinical and clinical pharmacology headings and that there is no manufacturing section. It is also more demanding than the company’s summary. The agency described participants who could not open the pouch, tore the film, placed it in the wrong part of the mouth or chewed it, and said the effect of chewing or misplacement on pharmacokinetics and clinical efficacy “is uncertain”. It noted that the original human factors study used a placebo with a different formulation, and asked for the new study to use a placebo matching the real film.

Two further points carry weight. First, the letter states that “tolerability of dibutepinephrine sublingual film is a concern”, based on pediatric reports of tingling, burning or taste and on “the high rate of local adverse events reported in the pivotal PK trials”, and asks Aquestive to address it in the resubmission. Second, the clinical pharmacology section asked for exposure data under three conditions, chewed film with and without swallowing, alternative placement sites and self-administration with the final instructions, each compared with trained-staff dosing and an injected product. The letter adds that redesigning the packaging “will not obviate the need” for that work. It also records a citizen petition about Anaphylm filed on October 1, 2025 by ARS Pharmaceuticals, maker of the nasal spray neffy; the public docket lists a final FDA response posted on February 27, 2026. FDA letter → Docket FDA-2025-P-4612 →

Read side by side, the two accounts agree on the core problem, a rescue film that has to be opened and placed correctly under stress, but the company’s framing, “deficiencies limited to packaging and administration”, leaves out the tolerability question and the breadth of the pharmacokinetic request. The company did address tolerability in its August 10 materials: no participant in the new human factors study and no subject in the PK study removed the film prematurely, and the PK study had no serious adverse events and no adverse events leading to study drug discontinuation. Those are topline company data. Whether the September 17 resubmission answers both points is the FDA’s decision.

The cautious interpretation is that “fixable” is not the same as “fixed.” Human-factors failures can be stubborn because they involve real users, real stress scenarios, different training levels and different physical abilities. A design that seems better in theory still has to perform in validation. A label that seems clearer still has to reduce use errors. A PK study that seems supportive still has to show that changes in packaging, instructions and administration do not undermine the exposure profile regulators need to see.

The key analytical point is that the CRL narrowed the question but did not eliminate the binary nature of the story. Before the CRL, the binary question was approval versus rejection. After the CRL, the binary question becomes whether the repair package is accepted as adequate. The stock can still move sharply around each step because AQST’s valuation remains highly sensitive to Anaphylm.

13 The Type A Meeting and the Q3 2026 Resubmission Plan

The March 30, 2026 Type A meeting update is one of the most important pieces of the post-CRL record. Type A meetings matter because they are designed for stalled or urgent development programs, including situations after a CRL. For AQST, the goal was to understand exactly what FDA wanted in the human-factors and PK work and whether the company’s proposed path could support resubmission in 2026.

Aquestive said it received clarifying feedback from FDA on pharmacokinetic and human-factors study designs. The company also said it had general alignment with FDA on key human-factors study elements, including user groups, and that it planned to submit the human-factors protocol for FDA review as recommended. FDA also acknowledged changes made to the container closure, which are intended to improve opening and reduce the risk of tearing the film; those changes were subsequently tested in the human-factors study reported August 10.

On PK, Aquestive said most of FDA’s preliminary comments focused on consistency between past PK studies and the proposed current design. The company also said FDA and Aquestive aligned on using labeling language to manage potential chewing of the film rather than creating additional clinical data. This detail matters because chewing could have become a more difficult behavioral variable if FDA required a larger clinical program to address it.

As of the Q1 2026 update, management continued to guide to a Q3 2026 NDA resubmission, subject to completion of the required studies and expected FDA response timelines. Investors should separate management guidance from confirmed FDA review outcome. The company can target Q3. The FDA accepted the resubmission as complete and classified it as Class 2 on October 15, 2026.

For traders, the cleanest way to monitor the next stage is to track four gates: announcement that the human-factors validation study is complete; announcement or confirmation that the supportive PK study is complete; formal resubmission in Q3 2026; and FDA acceptance and classification, answered on October 15: Class 2, with a PDUFA goal date of March 16, 2027.

The first two gates closed on August 10, 2026. Both studies read out together, both were described as supportive of resubmission, and the company kept the third-quarter target in its August 11 earnings release. The third gate closed on September 17, 2026, when the resubmission was announced. The FDA answered on October 15: a Class 2 classification and a PDUFA goal date of March 16, 2027.

What the two studies measured

The table below sets the resubmission human factors study against the study behind the original NDA, using the five behaviours the FDA identified in the Complete Response Letter. The two studies enrolled different numbers of participants, so each count is shown with its denominator.

Percentages are calculated from the participant counts published by the company on August 10, 2026. The 15.7% figure covers participants whose difficulty could have delayed a dose, prevented administration or caused underdosing.

The sample sizes matter when reading the pharmacokinetic study. The self-administration arm enrolled 24 healthy volunteers, the clinician-administered film and intramuscular arms 48 each, and the geometric coefficient of variation for peak concentration was about 137% and 130% for the two film arms against 67% for the injection, so individual exposure varied widely. All 24 self-administering volunteers opened the pouch and placed the film under the tongue as instructed. The arm in which clinicians deliberately placed the film on top of the tongue (24 volunteers) reached a geometric mean peak of 112.7 pg/mL at a median 35 minutes, against 334.5 pg/mL at 45 minutes for the injection; the company describes the blood-pressure and heart-rate response in that arm as clinically meaningful. The materials do not report a chewed-film arm, the first of the three conditions the FDA listed; for the second condition, alternative placement sites such as the top of the tongue or the roof of the mouth, they report only the top-of-tongue arm. In March the company said it and the FDA had “aligned on the concept” of managing potential chewing through labeling language rather than new clinical data, while the January letter had said design changes “will not obviate the need” for the pharmacokinetic work. August 10 study slides →

14 Global Regulatory Strategy: Canada First, EU Next and UK During 2027

The U.S. resubmission remains the main equity driver, but Aquestive is building an ex-U.S. sequence. The August 11 release says the company remains on track to file in Canada by the end of 2026, in the European Union in Q1 2027 and in additional markets including the United Kingdom during 2027.

The company’s headline description—beginning ex-U.S. filings in Q4 2026—is consistent with a Canada-first sequence. It should not be misread as simultaneous approval applications in every region. Canada, the EU and the UK have different procedural requirements, review clocks and commercial partners.

The targets have already moved once. On January 9, 2026 the company expected to file in Canada in the first half of 2026 and in Europe in the second half; after the complete response letter they became the end of 2026 and the first quarter of 2027, and the September 23 presentation repeats those later dates. January 9 release →

Aquestive believes existing clinical data can support those filings, and prior updates described engagement with the UK regulator and an initial Pediatric Investigation Plan in Europe. Those are constructive preparatory steps, not regulatory acceptance or marketing authorization.

International expansion can enlarge the long-term opportunity and create out-licensing possibilities, but it also adds cost and execution complexity. Management says it continues to evaluate ex-U.S. out-licensing for Anaphylm. A partnership could bring non-dilutive economics or local expertise, but as of October 15, 2026 Aquestive had not announced such a transaction.

15 Commercial Readiness: an Allergist-First Launch and a Heavier Second-Half Cost Base

September 29, 2026 update. Daly’s background includes building commercial organizations and launches across larger pharmaceutical and biotechnology businesses. Aquestive explicitly links his appointment to preparation for a potential Anaphylm launch if FDA approves it. Experience at board level is not evidence that reimbursement, distribution, prescriber adoption or launch economics have been secured. These remain operational questions for subsequent disclosures. Company source

Aquestive is preparing for a focused, allergist-first U.S. launch as quickly as possible after approval. Medical affairs is already engaging the allergy community, the company has expanded its Scientific Advisory Board, continues working with patient-advocacy organizations and is conducting payer engagement and market-access planning.

The first-quarter 2026 release of May 13 expanded the planned field force to approximately 75 representatives from 50. The August 11 release did not withdraw that plan, but it emphasized focus and discipline rather than restating the headcount. Future management updates should clarify hiring cadence, outsourced versus internal roles and how much commitment occurs before FDA acceptance and a new action date.

This matters because Anaphylm will not sell itself. Physicians and payers must understand how the film compares with generic and branded autoinjectors and nasal epinephrine. Patients and caregivers must trust the product under emergency conditions. Schools, camps and other institutional settings may require education, storage policies and confidence in the label.

The unchanged adjusted EBITDA guidance suggests that the expensive part of preparation may occur in the second half. That spending can create value if approval and launch remain on schedule; it can destroy flexibility if the resubmission slips or FDA requires more work. The highest-quality strategy would stage commitments around documented regulatory gates rather than around internal confidence alone.

The September 23 presentation lists the launch-readiness work as unbranded medical education, payer awareness, advocacy and congress activity, and states that commercial infrastructure is built. It also cites a company survey in which 51 of 53 patients and caregivers preferred a placebo film to an empty nasal device; the company itself warns that stated preferences in a survey do not predict prescribing or use, and it notes that no head-to-head study against neffy has been run. September 23 presentation →

16 Financial Position, Oaktree Facility, Future-Revenue Obligations and Dilution Risk

Aquestive ended Q2 2026 with $98.490 million of cash and equivalents, down from $110.734 million at March 31 and $121.169 million at year-end 2025. The release did not include a cash-flow statement, and the quarter contained debt refinancing flows, so the $12.244 million sequential cash decline is not pure operating burn.

The Oaktree facility has a headline maximum of $150 million, but only $55 million was funded at the May closing, primarily to repay $45 million of old 13.5% notes and related amounts. The refinancing pushed scheduled principal to 2031 and created additional conditional capacity. Aquestive’s Q2 materials identify $20 million of additional Oaktree debt and $75 million under the RTW agreement as potentially available upon Anaphylm approval.

Those approval-contingent amounts should be scenario-weighted, not added to current cash. If Anaphylm is approved, they can support launch. If it is not approved, the company may need to preserve cash, cut spending, partner assets or use other financing tools.

The conditions are precise. The RTW agreement pays $75 million only if Anaphylm is approved by June 30, 2027; in return RTW receives a tiered revenue share of 1.0% to 7.5% of U.S. Anaphylm net sales, rising to 9.5% for a following year if sales miss a specified level, until it has received $187.5 million by December 31, 2035 or $225 million thereafter. Oaktree’s $150 million facility is a five-year loan maturing on May 12, 2031 with no amortization: $55 million drawn, a $20 million Tranche B available after an approval received before June 30, 2027, a $25 million Tranche C tied to a sales milestone and up to $50 million more by mutual consent. It carries floating interest at three-month SOFR (floor 2.75%) plus 6.25%, a first-priority lien on substantially all assets including intellectual property, and a minimum-cash covenant. Form 10-Q, Notes 1 and 13 →

The July 9 424B3 prospectus covers up to 230,271 shares underlying Oaktree Tranche A warrants with a $4.18 exercise price and May 2031 expiry. Against 125.512 million shares outstanding at June 30, that registered amount is about 0.18%, small in isolation. Additional warrants may accompany later Oaktree tranches.

Across all instruments, warrants over 2,965,819 shares were outstanding at June 30: 2.2 million at $2.60, 375,000 issued to RTW at $4.00 (expiring March 3, 2029), the 230,271 Oaktree warrants at $4.18 and 160,548 at $0.96. Three officers exercised 98,623 of the $0.96 warrants in September. The at-the-market programme remains open: 1,191,071 shares were sold in the first half of 2026, none in the second quarter, for about $4.8 million net, and about $73 million of capacity remained at June 30. The company states in the 10-Q that its cash, business and access to equity markets, including the ATM, fund operations for at least the next twelve months. Form 10-Q →

Historical dilution remains relevant. Q2 weighted-average basic and diluted shares were 124.994 million versus 99.327 million a year earlier, an increase of roughly 26%, largely reflecting capital raised between the comparison periods. The June 30 balance-sheet share count was 2.84% above year-end 2025. A small current warrant overhang does not erase the broader equity-financing history.

The clean conclusion is that liquidity is adequate for the immediate filing path, but launch funding is conditional and the capital stack is complex. Debt, royalty obligations, future-revenue claims and potential equity issuance all compete with common shareholders for the economics of successful products.

17 Libervant: Tentative Approval, a New Ages 6–11 Filing and a 2027 Access Window

Libervant is a diazepam buccal film for seizure clusters. FDA granted tentative approval in August 2022 for patients aged 12 and older after concluding that the relevant quality, safety and efficacy requirements were met, but Valtoco orphan-drug exclusivity prevented U.S. marketing.

FDA approved Libervant for patients aged two to five in April 2024, creating market access for that younger group. After Neurelis challenged the decision, a February 2025 court ruling led FDA to convert the pediatric approval to tentative approval and Aquestive stopped U.S. marketing. Legislation enacted in February 2026 amended the Orphan Drug Act in a way Aquestive believes supports FDA’s historical interpretation, but that has not yet restored commercial access.

The August 11 release adds a material development: Aquestive filed for FDA approval of Libervant in patients aged 6–11 during Q2 2026. That filing expands the regulatory map but does not guarantee approval or immediate market access. The company did not disclose an FDA action date in the release, and exclusivity plus procedural issues still require careful monitoring.

For patients aged 12 and older, the company expects Libervant to become eligible for full approval after competing orphan exclusivity expires in January 2027. Eligibility is not the same as automatic launch: FDA action, labeling, supply, payer coverage and commercial execution still have to follow.

The legal file has three open threads. The Valtoco exclusivity runs to January 10, 2027. The FDA’s appeal of the February 2025 ruling on the age 2–5 approval is before the D.C. Circuit, where the parties are briefing the effect of the February 3, 2026 amendment to the Orphan Drug Act and a decision is expected later this year, according to the 10-Q. And the company’s request of February 24, 2025 that the FDA recognise Libervant as clinically superior had received no answer by the 10-Q date. Form 10-Q, Legal Proceedings →

Aquestive’s February 2026 presentation estimated a potential annual revenue opportunity above $100 million for ages two to five and 12 and older after a possible 2027 launch. That is a company scenario, not current revenue, independent consensus or a guarantee. The new 6–11 filing may broaden future reach, but the company has not published a revised opportunity estimate in the Q2 materials.

On October 14, 2026 Aquestive licensed U.S. rights to Libervant exclusively to Eton Pharmaceuticals, which will commercialize it while Aquestive supplies the product under a 20-year agreement. The economics shift to a $10 million upfront fee, milestones of up to $47.5 million, mid-teens royalties and supply revenue, and Aquestive no longer carries a Libervant launch. Until full market access is confirmed, those payments should still be probability-weighted rather than booked as a 2027 certainty.

18 AQST-108 and AdrenaVerse: Atopic Dermatitis Moves Up the Priority List

AQST-108 is a topical epinephrine-prodrug gel built from Aquestive’s AdrenaVerse platform, a library of approximately 20 prodrugs designed to control absorption and conversion of epinephrine across dosage forms and delivery sites.

The completed Phase 1 study in androgenic alopecia identified no safety concerns according to the company, supporting continued development. Management is now emphasizing inflammatory dermatology, particularly atopic dermatitis, while keeping broader optionality in alopecia areata and other dermatologic or immunologic indications.

The proposed biology is immunomodulatory: epinephrine may stabilize mast cells, reduce histamine release and downregulate inflammatory mediators. That is a company development thesis, not clinical proof of efficacy in atopic dermatitis. The program remains too early for investors to project commercial penetration from mechanism alone.

The Q2 supplemental timeline places preclinical toxicology in the second half of 2026 and a single-ascending-dose/multiple-ascending-dose study in the first half of 2027. The company describes additional preclinical and clinical work across 2H 2026 and 1H 2027. Investors should monitor protocol, indication, formulation, endpoints and funding before assigning material stand-alone value.

AQST-108 remains optionality, not the primary AQST trade. Its strategic importance rises if Anaphylm validates the broader prodrug platform, but it cannot presently offset another major Anaphylm delay.

19 Management, Medical Leadership and Governance Watch

September 29, 2026 update. Richard “Rich” Daly joins the board effective October 14, following the September 29 announcement. The post-appointment board will comprise eight directors, seven determined independent under Nasdaq standards. His experience includes senior commercial and operating roles at AstraZeneca, Takeda and Catalyst; he currently serves as President of Global Rare Disease at Angelini Pharma, which acquired Catalyst Pharmaceuticals, where he was chief executive. He joins as a Class I director with a term to the 2028 annual meeting and an initial grant of 57,000 stock options. This is a board appointment, not a change of CEO or a grant of regulatory authorization. Company source

CEO Daniel Barber is navigating a compressed sequence: CRL repair, Q3 resubmission, a possible expedited review, international filings and preparation for an allergist-first launch in 2027. The August 11 release used the phrase “coming weeks” for resubmission while retaining the formal Q3 window, and the filing was submitted on September 16 and announced on September 17, so that execution standard was met.

Dr. Matthew Greenhawt’s role as Chief Medical Officer fits the company’s current needs. Anaphylm requires credibility with allergists, patient organizations and payers, while the resubmission requires precise medical and regulatory communication. Medical leadership is central rather than decorative in an emergency-treatment launch.

The main management question after Q2 is spending discipline. Unchanged adjusted EBITDA guidance implies substantially heavier second-half losses than the first half. Management needs to connect that spend to concrete regulatory and commercial milestones, distinguish reversible from committed costs and explain how hiring is staged before the FDA decision on the resubmission.

Governance monitoring should also cover use of approval-contingent debt, any ATM activity, the execution of the Libervant license with Eton, ex-U.S. Anaphylm out-licensing, executive severance and share-based compensation, and the balance between retaining product economics and protecting the cash runway. The legal function changed hands this year: Lori Braender stepped down as Chief Legal Officer on April 2, 2026 under a separation agreement with accelerated vesting, and Thomas A. Zalewski holds the role. Separately, second-quarter SG&A rose partly because of about $1.4 million of higher severance costs, including accelerated share-based compensation. Form 8-K, March 20 →

20 Insider Activity and June 2026 Governance Watch

Daniel Barber reported selling 25,000 shares on August 17 at a weighted-average $4.2867, with 585,574 shares directly held afterward. The Form 4 identifies the sale as made under a Rule 10b5-1 plan. Sherry Korczynski’s August 14 transaction involved 2,714 shares withheld for RSU taxes, not an open-market sale. A Form 144 reports a proposed sale, not an additional completed sale.

September added more activity, all filed on Forms 4. Chief Operating Officer Cassie Jung (September 3, 4,587 shares), Barber (September 8, 91,743 shares) and Chief People Officer Peter Boyd (September 9, 2,293 shares) exercised for cash warrants at $0.96 dating from the June 2022 financing; none sold those shares in the same filing. Chief Commercial Officer Sherry Korczynski exercised 8,750 options at $2.65 and sold the same 8,750 shares at $5.22 on September 9 under a Rule 10b5-1 plan. Barber sold another 25,000 shares on September 15 at a weighted average of $4.8195, also under a 10b5-1 plan, leaving 652,317 shares held directly; his Form 144 of that day covered up to 50,000. On October 15 he sold a further 25,000 shares at a weighted average of $4.2240, again with the Rule 10b5-1 box checked, leaving 627,317 shares held directly. Open-market sales by officers since mid-August total 83,750 shares, about $0.38 million at the filed prices (Merlintrader calculation); no open-market purchases were reported. Barber, September 15 · Barber, October 16 · Korczynski, September 9 · all Forms 4

At the June 10, 2026 annual meeting shareholders re-elected Gregory B. Brown, John S. Cochran and Abigail L. Jenkins as Class II directors, approved executive pay on an advisory basis and ratified KPMG as auditor. Cochran received 5,680,845 withheld votes against 36,914,899 for, the weakest result of the three. Form 8-K, June 10 →

Barber — Form 4 · Korczynski — Form 4

21 Institutional Ownership, Capital Flows and Index Watch

AQST is the type of stock where institutional behavior can matter, but it must be interpreted carefully. Small-cap biotech ownership changes can reflect many different strategies: event-driven positioning ahead of regulatory catalysts, healthcare specialist accumulation, passive ETF flows, quantitative rebalancing, market-making inventory, or financing-related ownership. A filing does not automatically mean “smart money knows approval is coming.” It means a position exists at a point in time, often with incomplete context.

Two holders have filed above the 5% threshold. BlackRock reported 7,992,647 shares, 6.4% of the class, at June 30, 2026 on a Schedule 13G/A of July 27, up from 5.3% at September 30, 2025. RTW Investments and Roderick Wong reported 6,250,000 shares, 5.2%, at September 30, 2025; RTW filed on Schedule 13G, which certifies that the shares are not held to change or influence control of the company; it is also the counterparty to the $75 million approval-contingent funding agreement, so in Merlintrader’s reading its economic interest goes beyond the shareholding. BlackRock 13G/A · RTW 13G

For AQST, the more useful institutional question is whether the company can remain investable for specialist funds through the resubmission window. The Oaktree facility helps because it reduces immediate balance-sheet pressure. The completed September 17 resubmission helps because it gives a defined calendar anchor, and the FDA has since set a March 16, 2027 PDUFA goal date. The clinical comparability statements help because they frame the CRL as bounded rather than devastating. But the stock remains exposed to event risk, liquidity swings and dilution concerns.

Index inclusion and passive-flow potential should be watched only as a technical scenario, not as a confirmed catalyst. If AQST’s market capitalization, float, liquidity and trading history improve materially into future small-cap index review windows, passive-flow interest could become relevant. At the current stage, however, the regulatory path is more important than index mechanics.

22 Retail Sentiment: Reddit, Stocktwits and X

October 5, 2026 platform indicators: sentiment score 29/100 (BEARISH) with 12,589 watchers, down from 38/100 on September 5. The tagged-message percentage points in a different direction and is a distinct measure from the normalized site score. These are platform indicators, not probabilities or a representative investor survey. Discussion since the resubmission has centred on the review class and the timing of an FDA answer; speculation does not confirm FDA developments.

StockTwits $AQST

23 Competitive and Market Positioning

Anaphylm would not enter an empty market. The rescue-epinephrine landscape is anchored by auto-injectors, including branded and generic options, and has also begun to evolve with needle-free alternatives such as nasal epinephrine. That competitive backdrop is central to how investors should frame the opportunity. Anaphylm does not only need FDA approval. It needs a reason to exist commercially after approval.

The core differentiation is device-free administration. A sublingual film could be easier to carry, more discreet, less intimidating and potentially more acceptable to patients who avoid needles. The question is whether those advantages translate into prescribing, payer coverage and real-world patient behavior. In a market where patients often fail to carry their rescue therapy consistently, convenience can matter. But payers and physicians will still want confidence in exposure, usability, safety, label clarity and emergency effectiveness.

The competitive question is therefore not “can Anaphylm replace every auto-injector?” A more realistic question is whether Anaphylm can carve out a meaningful segment: needle-averse patients, families seeking a smaller form factor, schools and caregivers focused on ease of carry, and physicians who see the film as a practical addition to the rescue toolkit. That would still require education, payer negotiation and field-force execution.

24 Merlintrader Bottom Line

September 29, 2026 update. The September 29 update adds a named director and a confirmed start date. It provides no new financial guidance, cash figure or approval timetable. The useful follow-through is whether the added commercial oversight translates into measurable readiness while the regulatory process advances. Company source

The August 11 release is operationally better than the headline $22.9 million loss. Revenue, manufacturing volume, gross margin, operating loss and adjusted EBITDA all moved in the right direction year over year. The one-time $11.7 million debt-extinguishment loss explains most of the deterioration in GAAP net loss.

The more important issue is forward spending. With $98.5 million of cash and unchanged guidance that implies a much larger second-half adjusted EBITDA loss, AQST is entering the expensive part of the Anaphylm story before the FDA decision on the resubmission. That does not create an immediate liquidity crisis, but it raises the value of disciplined staging and clear management explanations.

Anaphylm has been resubmitted, on September 16 (announced September 17), with the studies the CRL required. On October 15 the FDA accepted the response as complete and set a PDUFA goal date of March 16, 2027; the next true regulatory de-risking step is the agency’s decision, and the published letter shows that decision will also cover film tolerability and misuse pharmacokinetics, not only the pouch. June 30, 2027 is the date by which an approval unlocks the $95 million of contingent funding.

Libervant and AQST-108 broaden the story. Libervant now includes a disclosed ages 6–11 filing and a January 2027 access reference point for ages 12 and older. AQST-108 is expanding toward atopic dermatitis with additional work planned into 2027. Neither should be valued as current commercial certainty.

The balanced conclusion is that AQST has a credible regulatory-repair path, a stronger operating quarter and enough cash to reach the filing, but also a costly launch plan, approval-contingent financing, complex obligations and substantial historical dilution. The stock remains a document-driven catalyst name: resubmission, the March 16, 2027 PDUFA date, payer evidence, financing conditions and launch execution matter more than slogans.

25 Related Merlintrader Coverage

• Three Biotech Earnings Stories: $PGEN, $AQST and $ALLO
• Aquestive Therapeutics: Anaphylm After the CRL
• AQST + PHAR: January 31 PDUFA Countdown
• Free FDA & PDUFA Calendar
• Biotech Stocks Hub
• Complete Response Letters explained
• Dilution, ATM and PIPE guide